Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• Renal Function Improvement: Treatment with TransCon PTH (palopegteriparatide) significantly increased estimated glomerular filtration rate (eGFR) by a mean (standard deviation (SD)) of 9.3 (11.7) mL/min/1.73 m² at week 52 (P < 0.0001), with a larger mean (SD) increase of 11.5 (11.3) mL/min/1.73 m² (P < 0.001) observed in participants with baseline eGFR < 60 mL/min/1.73 m².
• Composite Efficacy Outcomes: At week 26, 79% (48/61) of participants receiving TransCon PTH achieved normal albumin-adjusted serum calcium levels, independence from conventional therapy, and no dose escalation, compared to 5% (1/21) in the placebo group (P < 0.0001).
• Secondary Outcomes: TransCon PTH significantly improved quality of life as measured by the Hypoparathyroidism Patient Experience Scale (HPES) (P < 0.01) and SF-36 Physical Functioning subscale (P = 0.0347). Additionally, 93% (57/61) of treated participants achieved normocalcemia and independence from conventional therapy during the 26-week period. 5. 82% (50/61) of participants treated with TransCon PTH (palopegteriparatide) experienced adverse events, with the majority being mild (46%) or moderate (46%); no study drug-related withdrawals occurred. In the placebo group, 100% (21/21) of participants experienced adverse events, including one case of nephrolithiasis during the blinded treatment phase.
• No cases of nephrolithiasis were reported in the TransCon PTH (palopegteriparatide) group through week 52.